YARDLEY, Pa.--(BUSINESS WIRE)--Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application ...

Xhance was evaluated in five trials enrolling >1,500 adults. Optinose announced that the Food and Drug Administration (FDA) has approved Xhance (fluticasone propionate) Nasal Spray for the treatment ...

Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose ...

YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...

Xhance (fluticasone propionate) is a brand-name nasal spray that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance has interactions with some other drugs, such as ...

The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...

YARDLEY, Pa., April 27, 2021 /PRNewswire/ — Optinose, (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

Optinose has filed to raise $100 million in an IPO. The filing comes days after the FDA approved the intranasal delivery specialist’s treatment for nasal polyps, the commercialization of which will be ...